PercuSurge Committed To Boston Scientific Carotid Stent Trial
This article was originally published in The Gray Sheet
Executive Summary
PercuSurge will proceed with plans to conduct U.S. trials of its GuardWire distal protection device with Boston Scientific's WallStent for carotid angioplasty, in spite of rival Medtronic's proposed purchase of the company for $225 mil., announced Oct. 19.
You may also be interested in...
Boston Scientific Carotid Stent 2004 Launch Will Court Vascular Surgeons
Boston Scientific will complete enrollment of its 775-patient U.S. pivotal carotid stent trial by year-end
Boston Scientific Carotid Stent 2004 Launch Will Court Vascular Surgeons
Boston Scientific will complete enrollment of its 775-patient U.S. pivotal carotid stent trial by year-end
Medtronic GuardWire Begins Controlled Roll-Out In U.S. Market
Medtronic PercuSurge is planning to submit an IDE application in the next two months for a 500-600 patient trial evaluating its GuardWire distal protection device in patients with acute myocardial infarction.